American Home Products settles fen-phen lawsuits for $3.75 billion
American Home Products has agreed to pay up to $3.75 billion to settlethe numerous lawsuits it has faced in the USA regarding its diet drugs Pondimin (fenfluramine) and Redux (dexfenfluramine; Marketletters passim), in what is believed to be the largest legal settlement ever against a pharmaceutical company. The proposed deal is open to all Redux or Pondimin users in the USA, regardless of whether they have lawsuits pending, and AHP has issued a lengthy summary of what the settlement entails, including a refund program for the cost of the drugs, medical screening, additional medical services or cash payments and substantial compensation in the event of serious heart valve problems.
Settlement "fair and equitable" - AHP
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze